Search Results - "Grimley, Michael S."

Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes by Lee, Lynn H, Gasilina, Anjelika, Roychoudhury, Jayeeta, Clark, Jason, McCormack, Francis X, Pressey, Joseph, Grimley, Michael S, Lorsbach, Robert, Ali, Siraj, Bailey, Mark, Stephens, Philip, Ross, Jeffrey S, Miller, Vincent A, Nassar, Nicolas N, Kumar, Ashish R

“…Many patients with histiocytic disorders such as Langerhans cell histiocytosis (LCH) or Erdheim-Chester disease (ECD) have treatment-refractory disease or…”
Get full text

Brincidofovir for Asymptomatic Adenovirus Viremia in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: A Randomized Placebo-Controlled Phase II Trial by Grimley, Michael S, Chemaly, Roy F, Englund, Janet A, Kurtzberg, Joanne, Chittick, Gregory, Brundage, Thomas M, Bae, Andrew, Morrison, Marion E, Prasad, Vinod K

“…Highlights • There is an unmet need for effective therapy for adenovirus infection in hematopoietic cell transplant recipients • Brincidofovir has potent…”
Get full text

Ruxolitinib as Salvage Therapy in Steroid Refractory Acute Graft Versus Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients by Khandelwal, Pooja, MD, Teusink-Cross, Ashley, PharmD, Nelson, Adam S, MD, Dandoy, Christopher E, MD, El-Bietar, Javier, MD, Marsh, Rebecca A, MD, Kumar, Ashish R, MD, PhD, Grimley, Michael S, MD, Davies, Stella M, MBBS, PhD, Jodele, Sonata, MD, Myers, Kasiani C, MD

“…Highlights • Ruxolitinib has a 45% overall response rate as salvage therapy in children with steroid- refractory acute graft versus host disease • Ruxolitinib…”
Get full text

A case of treatment‐resistant membranous nephropathy associated with graft versus host disease successfully treated with daratumumab by Benoit, Stefanie W., Khandelwal, Pooja, Grimley, Michael S.

“…Background Membranous nephropathy (MN) is the most common cause of glomerulopathy after hematopoietic cell transplantation (HCT), most often occurring in the…”
Get full text

Viral specific T cell therapy in kidney transplant recipients – A single‐center experience by Anand, Manish, Nysather, Jake, McGraw, Gregory, Apewokin, Senu, Khoury, Ruby, Grimley, Michael S, Bumb, Shalini, Govil, Amit

“…Background Viral infections such as adenovirus (ADV), BK virus (BKV), and cytomegalovirus (CMV) after kidney transplantation negatively impact outcomes in…”
Get full text

Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa by Khandelwal, Pooja, Yeh, Rosa F., Yu, Louie, Lane, Adam, Dandoy, Christopher E., El-Bietar, Javier, Davies, Stella M., Grimley, Michael S.

“…INTRODUCTION:We hypothesized that the addition of 4 doses of abatacept to our standard acute graft versus host disease (GVHD) prophylaxis would reduce the…”
Get full text

Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant by Khoury, Ruby, Grimley, Michael S., Nelson, Adam S., Leemhuis, Tom, Cancelas, Jose A., Cook, Eleanor, Wang, YunZu, Heyenbruch, Daria, Bollard, Catherine M., Keller, Michael D., Hanley, Patrick J., Lutzko, Carolyn, Pham, Giang, Davies, Stella M., Rubinstein, Jeremy D.

“…Reactivation or primary infection with double-stranded DNA viruses is common in recipients of solid organ transplants (SOTs) and is associated with significant…”
Get full text

Ruxolitinib for the Treatment of Chronic GVHD and Overlap Syndrome in Children and Young Adults by Wang, YunZu Michele, Teusink-Cross, Ashley, Elborai, Yasser, Krupski, M. Christa, Nelson, Adam S., Grimley, Michael S., Flannery, Amanda, Mehta, Parinda A., Bleesing, Jacob J., Chandra, Sharat, Kumar, Ashish R., Myers, Kasiani C., Davies, Stella M., Khandelwal, Pooja

“…Ruxolitinib, a JAK1/2 inhibitor, is used to treat chronic graft versus host disease (cGVHD) in adult allogeneic hematopoietic stem cell transplant patients,…”
Get full text

Single Site Experience of the use of Monoclonal Antibodies for the Treatment of COVID-19 in High-risk Pediatric and Young Adult Patients by Bahakel, Hannah, Murphy, Catherine, Frenck, Robert W., Grimley, Michael S., Marsh, Rebecca A., Paulsen, Grant C., Haslam, David B., Phillips, Christine L., Courter, Joshua, Spearman, Paul, Schulert, Grant, Danziger-Isakov, Lara

“…Effective therapeutic agents for the treatment of COVID-19 have been investigated since the onset of the pandemic. Monoclonal antibodies targeting the spike…”
Get full text

Tocilizumab for Treatment of Children and Young Adults With Severe Acute COVID-19: Experience at a Quaternary-care Children’s Hospital by Teoh, Zheyi, Danziger-Isakov, Lara, Courter, Joshua D., Frenck, Robert W., Grimley, Michael S., Marsh, Rebecca A., Paulsen, Grant C., Phillips, Christine L., Spearman, Paul, Chima, Ranjit S., Schulert, Grant S.

“…We describe the clinical characteristics and outcomes of 16 children and young adults with severe acute COVID-19 who were treated with tocilizumab. Patients…”
Get full text

Lower levels of vitamin A are associated with increased gastrointestinal graft-versus-host disease in children by Lounder, Dana T., Khandelwal, Pooja, Dandoy, Christopher E., Jodele, Sonata, Grimley, Michael S., Wallace, Gregory, Lane, Adam, Taggart, Cynthia, Teusink-Cross, Ashley C., Lake, Kelly E., Davies, Stella M.

“…Vitamin A promotes development of mucosal tolerance and enhances differentiation of regulatory T cells. Vitamin A deficiency impairs epithelial integrity,…”
Get full text

Viral‐specific T cells for Cytomegalovirus retinitis following hematopoietic stem cell transplantation: A success story by Montiel‐Esparza, Raul, Michalak, Suzanne M., Le, Anthony Huy Dinh, Or, Christopher, Nguyen, Quan Dong, Khoury, Ruby, Grimley, Michael S., Bertaina, Alice, Klinger, Edna, Shah, Ami J., Wood, Edward H.

“…Cytomegalovirus retinitis (CMVR) following hematopoietic stem cell transplantation (HCT) for a primary immunodeficiency is a rare but highly morbid condition…”
Get full text

Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients by Nelson, Adam S., Heyenbruch, Daria, Rubinstein, Jeremy D., Sabulski, Anthony, Jodele, Sonata, Thomas, Shawn, Lutzko, Carolyn, Zhu, Xiang, Leemhuis, Thomas, Cancelas, Jose A., Keller, Michael, Bollard, Catherine M., Hanley, Patrick J., Davies, Stella M., Grimley, Michael S.

“…BK polyomavirus (BKPyV) infection is a major complication of hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT). Treatment options are…”
Get full text

Limitations of HLH‐2004 criteria in distinguishing malignancy‐associated hemophagocytic lymphohistiocytosis by Gurunathan, Arun, Boucher, Alexander A., Mark, Melissa, Prus, Kristina M., O'Brien, Maureen M., Breese, Erin H., Mizukawa, Benjamin E., Absalon, Michael J., Nelson, Adam S., Jordan, Michael B., Grimley, Michael S., Lorsbach, Robert B., Rotz, Seth J., Mathanda, Reema, Kumar, Ashish R.

“…Hemophagocytic lymphohistiocytosis (HLH) is characterized by dysregulated immune activation.  Primary HLH involves hereditary deficits in cytotoxic lymphocytes…”
Get full text

Use of Teduglutide in the Management of Gastrointestinal Graft-versus-Host Disease in Children and Young Adults by Ramos, Kristie N., Leino, Daniel, Luebbering, Nathan, Grimley, Michael S., Badia, Priscila, Davies, Stella M., Khandelwal, Pooja

“…•Teduglutide is a promising adjunctive nonimmune suppressive treatment for GI GVHD.•Addition of teduglutide facilitated endoscopy-confirmed resolution of GI…”
Get full text

Incidence of thyroid dysfunction in children after HSCT with reduced intensity conditioning (RIC) or myeloablative conditioning (MAC) by Wang, YunZu M., Howell, Jonathan C., Grimley, Michael S., Lane, Adam, Davies, Stella M., Myers, Kasiani C.

“…We have previously demonstrated a 11% incidence of post‐transplant de novo thyroid disease, even with a radiation‐free RIC regimen. Following the enactment of…”
Get full text

Experience with a Reduced Toxicity Allogeneic Transplant Regimen for Non-CGD Primary Immune Deficiencies Requiring Myeloablation by Chandra, Sharat, Chandrakasan, Shanmuganathan, Dávila Saldaña, Blachy J., Bleesing, Jack J., Jordan, Michael B., Kumar, Ashish R., Grimley, Michael S., Krupski, Christa, Davies, Stella M., Khandelwal, Pooja, Marsh, Rebecca A.

“…Purpose A need exists for reduced toxicity conditioning regimens that offer less toxicity while maintaining myeloablation, especially for primary immune…”
Get full text

Early stool microbiome and metabolome signatures in pediatric patients undergoing allogeneic hematopoietic cell transplantation by Elgarten, Caitlin W., Tanes, Ceylan, Lee, Jung‐Jin, Danziger‐Isakov, Lara A., Grimley, Michael S., Green, Michael, Michaels, Marian G., Barnum, Jessie L., Ardura, Monica I., Auletta, Jeffery J., Blumenstock, Jesse, Seif, Alix E., Bittinger, Kyle L., Fisher, Brian T.

“…Background The contribution of the gastrointestinal tract microbiome to outcomes after allogeneic hematopoietic cell transplantation (HCT) is increasingly…”
Get full text

Bortezomib for Refractory Autoimmunity in Pediatrics by Khandelwal, Pooja, Davies, Stella M, Grimley, Michael S, Jordan, Michael B, Curtis, Brian R, Jodele, Sonata, Marsh, Rebecca, Filipovich, Alexandra J

“…Abstract Therapy of refractory autoimmunity remains challenging. In this study, we evaluated the therapeutic effect of bortezomib, a proteasome inhibitor, by…”
Get full text

Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults by Galletta, Thomas J., Lane, Adam, Lutzko, Carolyn, Leemhuis, Thomas, Cancelas, Jose A., Khoury, Ruby, Wang, YunZu M., Hanley, Patrick J., Keller, Michael D., Bollard, Catherine M., Davies, Stella M., Grimley, Michael S., Rubinstein, Jeremy D.

“…•Virus-specific T cells are obtained from a patient's stem cell donor or a third-party volunteer.•Fiscal/infrastructural barriers limit the use of…”
Get full text